Literature DB >> 23555170

Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma.

Chang Liu1, Guang-Qin Xiao, Lu-Nan Yan, Bo Li, Li Jiang, Tian-Fu Wen, Wen-Tao Wang, Ming-Qing Xu, Jia-Yin Yang.   

Abstract

AIM: To explore the relationship between α-fetoprotein (AFP) and various clinicopathological variables and different staging system of hepatocellular carcinoma (HCC) thoroughly.
METHODS: A retrospective cohort study of consecutive patients diagnosed with HCC between January 2008 and December 2009 in West China Hospital was enrolled in our study. The association of serum AFP values with the HCC clinicopathological features was analysed by univariate and multivariate analysis, such as status of hepatitis B virus (HBV) infection, tumor size, tumor number, vascular invasion and degree of tumor differentiation. Also, patients were divided into four groups at the time of enrollment according to different cutoff values for serum value of AFP (≤ 20 μg/L, 21-400 μg/L, 401-800 μg/L, and ≥ 801 μg/L), to compare the positive rate of patient among four groups stratified by various clinicopathological variables. And the correlation of different kinds of tumor staging systems, such as TNM, Barcelona Clinic Liver Cancer (BCLC) staging classification and China staging, were compared with the serum concentration of AFP.
RESULTS: A total of 2304 HCC patients were enrolled in this study totally; the mean serum level of AFP was 555.3 ± 546.6 μg/L. AFP levels were within the normal range (< 20 μg/L) in 27.4% (n = 631) of all the cases. 81.4% (n = 1875) patients were infected with HBV, and those patients had much higher serum AFP level compared with non-HBV infection ones (573.9 ± 547.7 μg/L vs 398.4 ± 522.3 μg/L, P < 0.001). The AFP level in tumors ≥ 10 cm (808.4 ± 529.2 μg/L) was significantly higher (P < 0.001) than those with tumor size 5-10 cm (499.5 ± 536.4 μg/L) and with tumor size ≤ 5 cm (444.9 ± 514.2 μg/L). AFP levels increased significantly in patients with vascular invasion (694.1 ± 546.9 μg/L vs 502.1 ± 543.1 μg/L, P < 0.001). Patients with low tumor cell differentiation (559.2 ± 545.7 μg/L) had the significantly (P = 0.007) highest AFP level compared with high differentiation (207.3 ± 420.8 μg/L) and intermediate differentiation (527.9 ± 538.4 μg/L). In the multiple variables analysis, low tumor cell differentiation [OR 6.362, 95%CI: 2.891-15.382, P = 0.006] and tumor size (≥ 10 cm) (OR 5.215, 95%CI: 1.426-13.151, P = 0.012) were independent predictors of elevated AFP concentrations (AFP > 400 μg/L). Serum AFP levels differed significantly (P < 0.001) in the D stage of BCLC (625.7 ± 529.8 μg/L) compared with stage A (506.2 ± 537.4 μg/L) and B (590.1 ± 551.1 μg/L).
CONCLUSION: HCC differentiation, size and vascular invasion have strong relationships with AFP, poor differentiation and HCC size ≥ 10 cm are independent predictors of elevated AFP. BCLC shows better relationship with AFP.

Entities:  

Keywords:  Clinical features; Hepatocellular carcinoma; Pathological features; Tumor markers; α-fetoprotein

Mesh:

Substances:

Year:  2013        PMID: 23555170      PMCID: PMC3607758          DOI: 10.3748/wjg.v19.i11.1811

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 2.  Viral pathogenesis of hepatocellular carcinoma.

Authors:  Hubert E Blum; Darius Moradpour
Journal:  J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 4.029

3.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

4.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

Review 5.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

6.  Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation.

Authors:  Kathy Han; George N Tzimas; Jeffrey S Barkun; Peter Metrakos; Jean L Tchervenkov; Nir Hilzenrat; Phil Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-01       Impact factor: 3.522

7.  Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma.

Authors:  T J Tsai; G Y Chau; W Y Lui; S H Tsay; K L King; C C Loong; C Y Hsia; C W Wu
Journal:  Surgery       Date:  2000-06       Impact factor: 3.982

8.  Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.

Authors:  Irene L Ang; Terence C W Poon; Paul B S Lai; Anthony T C Chan; Sai-Ming Ngai; Alex Y Hui; Philip J Johnson; Joseph J Y Sung
Journal:  J Proteome Res       Date:  2006-10       Impact factor: 4.466

9.  Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein.

Authors:  H Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M Tanaka
Journal:  J Gastroenterol Hepatol       Date:  2001-12       Impact factor: 4.029

10.  Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.

Authors:  Wei Wu; Deng-Fu Yao; Yong-Mei Yuan; Ji-Wei Fan; Xiu-Feng Lu; Xiao-Hua Li; Li-Wei Qiu; Lei Zong; Xin-Hua Wu
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2006-11
View more
  49 in total

Review 1.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

2.  Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma.

Authors:  Yuan Hong; Yibing Peng; Z Sheng Guo; Jose Guevara-Patino; Junfeng Pang; Lisa H Butterfield; Nahid F Mivechi; David H Munn; David L Bartlett; Yukai He
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

Review 3.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

4.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

5.  Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT.

Authors:  Xiaohong Ma; Jingwei Wei; Dongsheng Gu; Yongjian Zhu; Bing Feng; Meng Liang; Shuang Wang; Xinming Zhao; Jie Tian
Journal:  Eur Radiol       Date:  2019-02-15       Impact factor: 5.315

Review 6.  Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects.

Authors:  Yukai He; Yuan Hong; Gerald J Mizejewski
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

7.  Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma.

Authors:  Sevil Uygun Ilikhan; Muammer Bilici; Hatice Sahin; Ayşe Semra Demir Akca; Murat Can; Ibrahim Ilker Oz; Berrak Guven; M Cagatay Buyukuysal; Yucel Ustundag
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

8.  Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers.

Authors:  Haruki Kimura; Kazuyoshi Ohkawa; Masanori Miyazaki; Mitsuru Sakakibara; Kazuho Imanaka; Takeshi Tamura; Hironari Sueyoshi; Ryoji Takada; Nobuyasu Fukutake; Hiroyuki Uehara; Reiko Ashida; Tatsuya Ioka; Tetsuro Nakazawa; Katsuyuki Nakanishi; Kazuhiro Katayama
Journal:  Hepatol Int       Date:  2016-10-20       Impact factor: 6.047

9.  Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages.

Authors:  Gui-Min Hou; Hai-Ling Liu; Hong Wu; Yong Zeng
Journal:  Ann Surg Oncol       Date:  2021-04-26       Impact factor: 5.344

10.  GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.

Authors:  Wey-Ran Lin; Chao-Wei Hsu; Yi-Cheng Chen; Ming-Ling Chang; Kung-Hao Liang; Ya-Hui Huang; Chau-Ting Yeh
Journal:  Mol Clin Oncol       Date:  2014-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.